The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•26 February 2026•

1 min read

argenx Reports 90% Revenue Surge in 2025 as Prosafe Issues Q4 Financial Results

A man in a suit over a stock chart with 'Mondelez International' text, surrounded by chocolate, cocoa beans, factories, and shops.

Key Facts

1argenx reported $4.2 billion in full-year 2025 net sales, representing 90% year-over-year growth.

2argenx's fourth-quarter sales alone reached $1.3 billion.

argenx (ARGX) announced stellar financial results for the full year 2025, highlighting a significant expansion in its market presence within the biotechnology sector. The firm reported net sales of $4.2 billion, marking a robust 90% increase compared to the previous year. In the fourth quarter alone, argenx generated $1.3 billion in revenue, underscoring strong momentum heading into the new fiscal year. Meanwhile, Prosafe SE (PRSO.OL) released its fourth-quarter earnings report, which included cautionary statements regarding its future outlook and potential industry risks. These results highlight a clear contrast between the explosive growth of healthcare innovators and the ongoing challenges in the offshore services market. Investors are closely monitoring these reports to gauge growth sustainability across different sectors.